Afuco™ Anti-Human CD44 ADCC Recombinant Antibody (RG7356), ADCC Enhanced (CAT#: AFC-122CL)

Figure 1 Pharmacokinetic assessments.

RG7356 serum concentration versus time plot in patients in Arm A who received the biweekly (q2w) (A) and weekly (qw) (B) dosing schedules

Menke-van der Houven,C.W.,van Oordt,C.G.R.,van Herpen, C.,Coveler, A. L.,Mahalingam, D., Verheul, H. M.,& Cannarile, M. A.(2016).First-in-human phase I clinical trial of RG7356,an anti-CD44 humanized antibody,in patients with advanced, CD44-expressing solid tumors.Oncotarget,7(48),80046.

Figure 2 Waterfall plot showing best response of individual patients according to RECIST criteria.

Of 61 evaluable patients, 21% (13/61) had stable disease (SD) as best response 45 patients had tumor lesion evaluation during the study. Abbreviations: PD (progressive disease); SD (stable disease).

Menke-van der Houven,C.W.,van Oordt,C.G.R.,van Herpen, C.,Coveler, A. L.,Mahalingam, D., Verheul, H. M.,& Cannarile, M. A.(2016).First-in-human phase I clinical trial of RG7356,an anti-CD44 humanized antibody,in patients with advanced, CD44-expressing solid tumors.Oncotarget,7(48),80046.

Figure 3 RG7356 induces a temporary reduction from baseline of CD14+ peripheral blood monocytes after first infusion.

(A),does not seem to have an effect on macrophage tumor infiltration (B), and generates a temporary release in cytokines. The latter seems to be independent of dose and/or dose-schedules (C-F). Dose-limiting toxicities (DLTs) occurred in 3 patients during the study: grade 3 febrile neutropenia on study day 18 and 2 cases of headache on study days 4 and 8 (C-F). Abbreviations: C (cycle); D (day); EOI (end of infusion); IL (interleukin); MCP-1 (monocyte chemoattractant protein-1); q2w (biweekly). A. Plot of mean changes from baseline of percent of CD14+ (± standard deviation) at RG7356 doses ≥300 mg for the q2w schedule. B. Waterfall plot of percent change in CD68+ macrophages. C.-F. Individual cytokine profiles.

Menke-van der Houven,C.W.,van Oordt,C.G.R.,van Herpen, C.,Coveler, A. L.,Mahalingam, D., Verheul, H. M.,& Cannarile, M. A.(2016).First-in-human phase I clinical trial of RG7356,an anti-CD44 humanized antibody,in patients with advanced, CD44-expressing solid tumors.Oncotarget,7(48),80046.

Figure 3 RG7356 induces a temporary reduction from baseline of CD14+ peripheral blood monocytes after first infusion.

The latter seems to be independent of dose and/or dose-schedules (C-D). Dose-limiting toxicities (DLTs) occurred in 3 patients during the study: grade 3 febrile neutropenia on study day 18 and 2 cases of headache on study days 4 and 8 (C-F). Abbreviations: C (cycle); D (day); EOI (end of infusion); IL (interleukin); MCP-1 (monocyte chemoattractant protein-1); q2w (biweekly). A. Plot of mean changes from baseline of percent of CD14+ (± standard deviation) at RG7356 doses ≥300 mg for the q2w schedule. B. Waterfall plot of percent change in CD68+ macrophages. C.-F. Individual cytokine profiles.

Menke-van der Houven,C.W.,van Oordt,C.G.R.,van Herpen, C.,Coveler, A. L.,Mahalingam, D., Verheul, H. M.,& Cannarile, M. A.(2016).First-in-human phase I clinical trial of RG7356,an anti-CD44 humanized antibody,in patients with advanced, CD44-expressing solid tumors.Oncotarget,7(48),80046.